SYNBIOMATICA

Daily briefings

Editor’s Briefing: November 17, 2026

In Short. The FDA approved Roche's Wilserdly in breast cancer and Novartis's Cosentyx in polymyalgia rheumatica. CG Oncology said its bladder cancer drug reduced recurrence. Helus said HLP003 met its depression-trial goal.

The FDA approves Roche's Wilserdly for a form of advanced breast cancer

ESTROGEN-RECEPTOR positive, HER2-negative breast cancer is driven by estrogen, a hormone, and not by the growth-signal protein HER2. On Monday the Food and Drug Administration approved Roche's Wilserdly (giredestrant), used with everolimus (announcement). The approval is for adults with locally advanced or metastatic disease that carries a change in the estrogen-receptor gene ESR1, after hormone treatment has failed. Wilserdly is a daily pill that blocks and helps break down the estrogen receptor. The mutation is found in as many as 40% of people with hormone-receptor-positive metastatic breast cancer.

The approval rests on evERA, a Phase 3 trial of 373 adults, including 207 whose tumors had ESR1 mutations. People were assigned at random to Wilserdly plus everolimus or to a doctor's choice of hormone therapy plus everolimus. In the group with those mutations, the combination reduced the risk of the cancer worsening or of death by 62% versus the comparator (hazard ratio 0.38, 95% confidence interval 0.27 to 0.54, p<0.0001). The median time without the cancer worsening was 10 months on the Wilserdly combination and 5.5 months on the comparator.

The FDA approves Novartis's Cosentyx for polymyalgia rheumatica

POLYMYALGIA RHEUMATICA is an inflammatory disease that causes pain and stiffness in the shoulders, neck, and hips. Late on Monday the FDA approved Novartis's Cosentyx (secukinumab) at 150 milligrams (announcement). The approval is for adults who have not had an adequate response to corticosteroid drugs, or who cannot tolerate a gradual reduction of those drugs. Cosentyx is an antibody that blocks interleukin-17, a signaling protein that can drive inflammation.

The approval is based on REPLENISH, a Phase 3 trial with three arms: Cosentyx 150 milligrams, Cosentyx 300 milligrams, or placebo, each with a 24-week planned reduction in steroid dose. At week 52, 40.5% of people on the approved 150 milligram dose had a sustained remission, compared with 20.5% of people on placebo. Serious unwanted effects occurred in 15.9% of people on the 150 milligram dose and in 14.2% of people on placebo. One person on Cosentyx died of cryptococcal meningitis, a fungal infection of the membranes around the brain.

CG Oncology reports that cretostimogene reduced recurrence after bladder tumor removal

NON-MUSCLE INVASIVE bladder cancer is cancer that has not grown into the muscle wall of the bladder. On Monday CG Oncology reported results from PIVOT-006, a Phase 3 trial of cretostimogene grenadenorepvec (announcement). The drug was given after complete removal of intermediate-risk tumors and of high-grade Ta tumors no larger than 3 centimeters. Cretostimogene is an experimental virus-based treatment placed into the bladder, designed to infect and kill cancer cells. The trial assigned 367 people at random to cretostimogene or to observation after surgery. The company said there is no FDA-approved added treatment in this group.

Median follow-up was 17 months. Cretostimogene reduced the risk that the cancer would come back by 68% versus observation (hazard ratio 0.32, 95% confidence interval 0.23 to 0.45, p<0.0001). No one had a grade 3 or worse treatment-related unwanted effect, and no one stopped treatment because of such effects.

Helus reports that HLP003 met its main goal in a Phase 3 depression trial

MAJOR DEPRESSIVE disorder is a common mental illness marked by persistent low mood. On Monday Helus Pharma reported results from APPROACH, a Phase 3 trial of HLP003 as an added treatment (announcement). The trial enrolled adults with moderate to severe disease who continued a stable antidepressant. HLP003 is deuterated psilocin, a modified form of the compound made in the body from the psychedelic substance psilocybin. The trial assigned 222 people at random. The main goal was the change at week 6 on the Montgomery-Asberg Depression Rating Scale, a standard depression-symptom score.

The average score fell by 19.5 points among 112 people on HLP003 and by 11.9 points among 110 people on placebo, a difference of 7.6 points (p<0.0001). At week 6, 56.3% of the 112 people on HLP003, and 28.2% of the 110 people on placebo, had a 50% or greater drop in the score. A score of 10 or lower was reached by 50.9% versus 18.2% of those groups. Three people had treatment-related serious unwanted effects, which the company did not describe.

What to watch

By November 22 the FDA is due to decide on Capricor's deramiocel for Duchenne muscular dystrophy, and on Savara's inhaled molgramostim. A decision on BridgeBio's BBP-418 is due on November 27, and on Roche's application to use Wilserdly after earlier-stage surgery by November 30.

Sources

  1. Roche: FDA approves Wilserdly (giredestrant) in ESR1-mutated advanced breast can
  2. Novartis: Cosentyx first anti-IL-17 biologic approved in polymyalgia rheumatica
  3. CG Oncology: PIVOT-006 Phase 3 cretostimogene topline in NMIBC
  4. Helus Pharma: positive Phase 3 APPROACH topline for HLP003 in MDD